Valuation Genmab A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 12:01:37 19/09/2024 BST			5-day change	1st Jan Change
1,768.50 ^DKK	+0.51%		-0.59%	-17.94%

09-16	Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug	MT
09-16	Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	96,408	161,105	172,063	192,229	140,770	111,739	-	-
Change	-	67.11%	6.8%	11.72%	-26.77%	-20.62%	-	-
Enterprise Value (EV) ¹	85,618	145,026	152,725	169,905	112,635	87,481	82,256	74,106
Change	-	69.39%	5.31%	11.25%	-33.71%	-22.33%	-5.97%	-9.91%
P/E ratio	43.5x	34.1x	57.8x	35.2x	32.6x	21.3x	18.7x	14.6x
PBR	6.85x	8.5x	7.82x	7.07x	4.5x	3.37x	2.82x	2.34x
PEG	-	0x	-1.6x	0.4x	-1.5x	0.9x	1.3x	0.5x
Capitalization / Revenue	18x	15.9x	20.3x	13.2x	8.54x	5.35x	4.55x	3.87x
EV / Revenue	16x	14.3x	18x	11.6x	6.84x	4.19x	3.35x	2.57x
EV / EBITDA	30.8x	22.1x	46.8x	25.3x	20.1x	13.7x	10.1x	7.16x
EV / EBIT	32.5x	23x	50.6x	26.7x	21.2x	14.4x	10.6x	7.37x
EV / FCF	68.7x	23.7x	77.3x	47.3x	16.1x	30.1x	12.9x	9.3x
FCF Yield	1.46%	4.22%	1.29%	2.12%	6.23%	3.32%	7.73%	10.7%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	34.03	72.21	45.54	83.65	66.02	82.51	94.09	120.2
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	5,366	10,111	8,482	14,595	16,474	20,874	24,585	28,860
EBITDA ¹	2,777	6,572	3,266	6,719	5,616	6,375	8,174	10,348
EBIT ¹	2,638	6,313	3,018	6,357	5,321	6,072	7,748	10,060
Net income ¹	2,166	4,758	3,008	5,522	4,352	5,406	6,318	8,078
Net Debt ¹	-10,790	-16,079	-19,338	-22,324	-28,135	-24,258	-29,483	-37,633
Reference price ²	1,481.50	2,463.00	2,630.00	2,941.00	2,155.00	1,759.50	1,759.50	1,759.50
Nbr of stocks (in thousands)	65,075	65,410	65,423	65,362	65,322	63,506	-	-
Announcement Date	19/02/20	23/02/21	16/02/22	22/02/23	14/02/24	-	-	-

¹DKK in Million²DKK

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield (Y)	Capi. ($)
GENMAB A/S	21.33x	4.19x	13.72x	-.--%	16.66B
VERTEX PHARMACEUTICALS INCORPORATED	-239.26x	10.46x	137.73x	-.--%	124B
REGENERON PHARMACEUTICALS, INC.	30.56x	8.03x	19.58x	-.--%	124B
ARGENX SE	-516.33x	14.17x	-172.25x	-.--%	31.62B
BIONTECH SE	-42.76x	4.53x	-12.8x	-.--%	29.65B
BEIGENE, LTD.	-33.02x	5.32x	-32.72x	-.--%	21B
WUXI APPTEC CO., LTD.	12.18x	2.59x	7.32x	+2.41%	16.12B
VAXCYTE, INC.	-26.01x	-	-	-.--%	14.44B
INSMED INCORPORATED	-14.02x	36.62x	-17.08x	-.--%	12.59B
Average	-89.70x	10.74x	-7.06x	+0.27%	43.34B
Weighted average by Cap.	-113.38x	9.48x	35.01x	+0.10%